• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BD launches fully-automated diagnostic to fight antimicrobial resistance in Europe

September 26, 2017 By Sarah Faulkner

Becton DickinsonBecton Dickinson (NYSE: BDX) today launched the first automated phenotypic diagnostic test for infections caused by carbapenemase-producing organisms.

The new BD Phoenix CPO test is available as part of the BD Phoenix automated microbiology system in Europe, the company said, and is designed to help hospitals detect and contain infections caused by CPOs.

Carbapenemase-producing organisms are resistant to nearly all available antibiotics, according to the CDC, and have earned a place on the World Health Organization’s priority pathogen list as critical threats to public health.

The BD Phoenix CPO detect test can accurately detect the organisms in under 36 hours, compared to 96 hours for conventional phenotypic methods, and can also provide the Ambler classification of the carbapenemase, the company said.

The test was designed to help hospitals and labs shape their infection response programs by facilitating rapid-detection of organisms and helping to select appropriate antibiotics, according to BD.

“The BD Phoenix CPO detect test is a completely new type of phenotypic test, and its range of capabilities is unmatched by all currently marketed tests,” Kenneth Thomson, clinical professor of pathology & laboratory medicine at the University of Louisville School of Medicine, said in prepared remarks. “It represents a significant advance in meeting an important clinical need.”

“The BD Phoenix CPO detect test gives laboratories an accurate and cost-effective method to rapidly identify CPOs and support patient management,” Steve Conly, VP of microbiology, added. “Along with the BD Phoenix M50, this first-to-market phenotypic automated test to detect CPOs, expands BD’s portfolio of solutions for identification and antimicrobial susceptibility testing (ID/AST) and is another example of the company’s commitment to combating AMR.”

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Diagnostics, Featured, Hospital Care, Wall Street Beat Tagged With: Becton Dickinson

IN CASE YOU MISSED IT

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Glucotrack can proceed with long-term glucose monitor study in Australia
  • Dexcom promotes Jake Leach to president role
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS